235 related articles for article (PubMed ID: 9072852)
1. [Thyroid stimulating antibodies in pregnant women with Graves' disease and neonatal thyrotoxicosis].
Nygaard B; Petersen JR; Jespersen NF
Ugeskr Laeger; 1997 Feb; 159(8):1086-9. PubMed ID: 9072852
[TBL] [Abstract][Full Text] [Related]
2. [Laboratory diagnosis before onset and prediction of Graves' disease].
Hidaka Y; Tada H; Amino N
Rinsho Byori; 1997 Sep; 45(9):825-30. PubMed ID: 9311254
[TBL] [Abstract][Full Text] [Related]
3. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
[TBL] [Abstract][Full Text] [Related]
4. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy.
Hidaka Y; Tamaki H; Iwatani Y; Tada H; Mitsuda N; Amino N
Clin Endocrinol (Oxf); 1994 Jul; 41(1):15-20. PubMed ID: 7914152
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of circulating thyroid-stimulating activities in pregnant women with Graves' disease: differential measurement of activities induced by TSH receptor antibody and hCG].
Kaneda T; Tamaki H; Hidaka Y; Amino N; Mitsuda N; Tanizawa O; Miyai K
Rinsho Byori; 1992 Sep; 40(9):941-7. PubMed ID: 1434029
[TBL] [Abstract][Full Text] [Related]
6. Universal predictive criteria for neonatal overt thyrotoxicosis requiring treatment.
Tamaki H; Amino N; Aozasa M; Mori M; Iwatani Y; Tachi J; Nose O; Tanizawa O; Miyai K
Am J Perinatol; 1988 Apr; 5(2):152-8. PubMed ID: 2450549
[TBL] [Abstract][Full Text] [Related]
7. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
[TBL] [Abstract][Full Text] [Related]
8. [Graves disease in pregnancy a risk for the child. Maternal TSH receptor antibodies can cause fetal and neonatal thyrotoxicosis].
Roos M; Sjöberg O; Axelsson O; Karlsson FA
Lakartidningen; 2008 Jan 16-22; 105(3):120-4. PubMed ID: 18290505
[No Abstract] [Full Text] [Related]
9. Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy.
Ide A; Amino N; Nishihara E; Kudo T; Ito M; Kimura Y; Tatsumi N; Yamazaki M; Miyauchi A
Endocr J; 2016 Oct; 63(10):929-932. PubMed ID: 27432817
[TBL] [Abstract][Full Text] [Related]
10. [Development of neonatal Graves' disease--prediction, prevention and treatment].
Matsuura N
Nihon Rinsho; 2006 Dec; 64(12):2303-7. PubMed ID: 17154096
[TBL] [Abstract][Full Text] [Related]
11. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
12. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
[TBL] [Abstract][Full Text] [Related]
13. Crucial role of serum human chorionic gonadotropin for the aggravation of thyrotoxicosis in early pregnancy in Graves' disease.
Tamaki H; Itoh E; Kaneda T; Asahi K; Mitsuda N; Tanizawa O; Amino N
Thyroid; 1993; 3(3):189-93. PubMed ID: 8257857
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism.
Zakarija M; McKenzie JM
J Clin Endocrinol Metab; 1983 Nov; 57(5):1036-40. PubMed ID: 6137493
[TBL] [Abstract][Full Text] [Related]
15. Thyroid cancer yield in patients with Graves' disease.
Stocker DJ; Burch HB
Minerva Endocrinol; 2003 Sep; 28(3):205-12. PubMed ID: 14605602
[TBL] [Abstract][Full Text] [Related]
16. The significance of thyroid-stimulating antibody (TSAb) in the management and prognostic evaluation of Graves disease.
Leövey A; Kálmán K; Bakó G; Szabó T
Acta Med Hung; 1985; 42(1-2):3-11. PubMed ID: 2863805
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunological follow-up of pregnant women with Graves disease.
Kálmán K; Leövey A; Szabó T
Acta Med Hung; 1986; 43(1):3-11. PubMed ID: 2877433
[TBL] [Abstract][Full Text] [Related]
18. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
19. Therapy insight: management of Graves' disease during pregnancy.
Chan GW; Mandel SJ
Nat Clin Pract Endocrinol Metab; 2007 Jun; 3(6):470-8. PubMed ID: 17515891
[TBL] [Abstract][Full Text] [Related]
20. Thyroxine excess and pregnancy.
Lazarus JH
Acta Med Austriaca; 1994; 21(2):53-6. PubMed ID: 7527990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
